can be divided into weekly or biweekly subcutaneous doses. Due to testosterone's viscosity, the vial and the syringe are warmed in the patients' palms or axilla for at least 5 min. This allows for easier withdrawal of the medication from the vial, quicker and more comfortable injections. We expect patients will report a preference for subcutaneous administration and may gain independence much earlier in their treatment regime. Clinical Implications: For youth who are requiring injectable testosterone, subcutaneous administration can lower the experiences of pain, provide more constant levels of testosterone and allow for easier self-injections. Once initial education has been completed and the patient is independent, fewer injections will need to be given by nurses or other health care providers in clinics, day units and at times pharmacies. This provides for anonymity and privacy for patients who can do the injections in the privacy of their home, thus decreasing the need to answer potentially unwanted questions especially for the transgender youth. Background: Children can be diagnosed with a disorder of sex development (DSD) at birth with ambiguous genitalia, or later in childhood after investigations of other symptoms. In all cases, the diagnosis comes as a surprise, and there is initial parental distress and uncertainty about their child's future. The diagnosis of DSD can have a significant impact on the psychosocial development and wellbeing of the child, with challenges around diagnosis complexity, sex of rearing, uncertain outcomes, treatment options and psychological stressors. Purpose: Whilst disclosure in practice often occurs in a gradual manner when working within a multidisciplinary team, we propose to formalise a guidance system describing a developmentally staged approach. The process involves sequential information about body parts, differences between male and female, the wide potential for gender roles and later the potential for different individual development of sex, gender, sexuality and fertility. Description of Topic: The development of gender identity begins after the first year of life, with children generally identifying with one sex by age three. Self-awareness regarding identity and gender role evolves during childhood, with sexuality developing through adolescents, along with physical secondary sex characteristics. Critical psychological development also starts to occur, including the capacity to understand concepts such as future fertility potential. Therapeutic events such as genital surgery or requirement for sex hormone therapy can affect this process. Information provided to a child about their diagnosis therefore needs to be age appropriate, and tailored to the individual's developmental needs. Criticism of past DSD management has been poor or late disclosure of diagnosis to the young person, and although advice now supports earlier disclosure, there is limited literature guiding a method for this. Clinical Implications: The goal of treatment is to ensure that the child's psychological, physical and sexual well-being are supported in a respectful and appropriate manner. This can be achieved via a multidisciplinary team working with the parents to support the child, communicating honestly and respectfully to maintain trust, and providing guided appropriate information through defined developmental stages from infancy to adolescence and adulthood. The paediatric endocrine nurse plays a critical role in this process as both child's advocate and family educator. Background: Congenital Hyperinsulinism (CH) is caused by unregulated, increased secretion of insulin from the pancreatic beta cells. This results in severe persistent hypoglycemia which can lead to brain injury. Diffuse disease can be treated medically. Previous practice at SickKids was to treat patients with diffuse disease who did not respond to oral diazoxide and who declined pancreatectomy or had persistent hyperinsulinism post-pancreatectomy with subcutaneous octreotide injected every 8 h. There have been some studies that conclude long acting somatostatin analogue (Lanreotide) is a safe and effective alternative to octreotide therapy in CH patients with a significant improvement in blood glucose (BG) control and quality of life. As a result, the new standard of care at SickKids is monthly deep subcutaneous Lanreotide injections. Purpose: To describe the new practice of injecting Lanreotide to children. To aim to educate pediatric endocrine nurses in its use, and understand the nursing implications involved. Description of Topic: We did a Literature review and emailed Great Ormond Street Hospital (GOSH) to obtain their experience. Patients came in monthly for Lanreotide injections. Pain management and distraction techniques were utilized. Octreotide was weaned by 25% each week following the second Lanreotide injection and ceased by third Lanreotide injection. Other therapies (e.g. sirolimus) weaned after octreotide discontinued if BG stable. Communicated with community partners to coordinate care for patients in their home town. Clinical Implications: The following nursing implications should be considered when patients are treated with Lanreotide: 1) Nursing Practice (dosing, injection technique, land marking, pain management, illness management) 2) Monitoring (GI upset, TFT, yearly ultrasound for cholelithiasis, BG, weaning of Octreotide/Sirolimus during treatment) 3) Patient/Family satisfaction.
Background: Children can be diagnosed with a disorder of sex development (DSD) at birth with ambiguous genitalia, or later in childhood after investigations of other symptoms. In all cases, the diagnosis comes as a surprise, and there is initial parental distress and uncertainty about their child's future. The diagnosis of DSD can have a significant impact on the psychosocial development and wellbeing of the child, with challenges around diagnosis complexity, sex of rearing, uncertain outcomes, treatment options and psychological stressors. Purpose: Whilst disclosure in practice often occurs in a gradual manner when working within a multidisciplinary team, we propose to formalise a guidance system describing a developmentally staged approach. The process involves sequential information about body parts, differences between male and female, the wide potential for gender roles and later the potential for different individual development of sex, gender, sexuality and fertility. Description of Topic: The development of gender identity begins after the first year of life, with children generally identifying with one sex by age three. Self-awareness regarding identity and gender role evolves during childhood, with sexuality developing through adolescents, along with physical secondary sex characteristics. Critical psychological development also starts to occur, including the capacity to understand concepts such as future fertility potential. Therapeutic events such as genital surgery or requirement for sex hormone therapy can affect this process. Information provided to a child about their diagnosis therefore needs to be age appropriate, and tailored to the individual's developmental needs. Criticism of past DSD management has been poor or late disclosure of diagnosis to the young person, and although advice now supports earlier disclosure, there is limited literature guiding a method for this. Clinical Implications: The goal of treatment is to ensure that the child's psychological, physical and sexual well-being are supported in a respectful and appropriate manner. This can be achieved via a multidisciplinary team working with the parents to support the child, communicating honestly and respectfully to maintain trust, and providing guided appropriate information through defined developmental stages from infancy to adolescence and adulthood. The paediatric endocrine nurse plays a critical role in this process as both child's advocate and family educator. Background: Congenital Hyperinsulinism (CH) is caused by unregulated, increased secretion of insulin from the pancreatic beta cells. This results in severe persistent hypoglycemia which can lead to brain injury. Diffuse disease can be treated medically. Previous practice at SickKids was to treat patients with diffuse disease who did not respond to oral diazoxide and who declined pancreatectomy or had persistent hyperinsulinism post-pancreatectomy with subcutaneous octreotide injected every 8 h. There have been some studies that conclude long acting somatostatin analogue (Lanreotide) is a safe and effective alternative to octreotide therapy in CH patients with a significant improvement in blood glucose (BG) control and quality of life. As a result, the new standard of care at SickKids is monthly deep subcutaneous Lanreotide injections. Purpose: To describe the new practice of injecting Lanreotide to children. To aim to educate pediatric endocrine nurses in its use, and understand the nursing implications involved. Description of Topic: We did a Literature review and emailed Great Ormond Street Hospital (GOSH) to obtain their experience. Patients came in monthly for Lanreotide injections. Pain management and distraction techniques were utilized. Octreotide was weaned by 25% each week following the second Lanreotide injection and ceased by third Lanreotide injection. Other therapies (e.g. sirolimus) weaned after octreotide discontinued if BG stable. Communicated with community partners to coordinate care for patients in their home town. Clinical Implications: The following nursing implications should be considered when patients are treated with Lanreotide: 1) Nursing Practice (dosing, injection technique, land marking, pain management, illness management) 2) Monitoring (GI upset, TFT, yearly ultrasound for cholelithiasis, BG, weaning of Octreotide/Sirolimus during treatment) 3) Patient/Family satisfaction. Background: Most health professionals are aware that the incidence of obesity in the pediatric population is rising. This is a largely preventable health problem with multifactorial causes that health care professionals are increasingly called upon to manage. Because there is no widely accepted referral path for obesity and patients may have endocrine consequences of poor lifestyle habits, endocrine clinics are frequently receiving referrals for these patients. Purpose: The purpose of this poster is to share information on a program experience that targeted improved management of obese patients, with goals to increase adoption of healthy habits and a decline in no-show rates. Methods used, problems encountered, and suggestions for management of obese patients will be presented.
